SCHEMBL25323809

SCHEMBL25323809

N[C@@H](CCC(=O)CP(=O)(O)O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 2/20 0.54
GRM6 O15303 2/20 0.54
GRM7 Q14831 2/20 0.54
GRM4 Q14833 2/20 0.54
GRIN2D O15399 2/20 0.54
GRIN3B O60391 2/20 0.54
GRIN1 Q05586 2/20 0.54
GRIN2A Q12879 2/20 0.54
GRIN2B Q13224 2/20 0.54
GRIN2C Q14957 2/20 0.54
GRIN3A Q8TCU5 2/20 0.54
GSR P00390 1/20 0.54
CYP1A2 P05177 1/20 0.54
GRIK1 P39086 1/20 0.54
GRM5 P41594 1/20 0.54
GRIA1 P42261 1/20 0.54
GRIA2 P42262 1/20 0.54
GRIA3 P42263 1/20 0.54
SLC1A3 P43003 1/20 0.54
SLC1A2 P43004 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4255161 1.00 GRM8 (0.54) GRM8GRM6GRM7GRM4GRIN2D
SCHEMBL9003756 0.89 OTC (0.58) GRM8GRM6GRM7GRM4GRIN2D
SCHEMBL9003744 0.89 OTC (0.58) GRM8GRM6GRM7GRM4GRIN2D
SCHEMBL27872833 0.80 ALOX15 (0.76) GRM8GRM6GRM7GRM4GRIN2D
SCHEMBL22164119 0.80 ALOX15 (0.76) GRM8GRM6GRM7GRM4GRIN2D
SCHEMBL8467545 0.79 OTC (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1431004 0.79 OTC (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL195547 0.79 OTC (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Glutamic Acid SCHEMBL49767 0.77 GRM8 (0.82) GRM8GRM6GRM7GRM4GRIN2D
D-Glutamate SCHEMBL1065173 0.77 GRM8 (0.82) GRM8GRM6GRM7GRM4GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4419094-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS Edison Oncology (US) 2024-08-28 EP disclosed
US-20240043878-A1 GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION SANOFI (FR) 2024-02-08 US disclosed
EP-4214308-A1 GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION Sanofi (FR) 2023-07-26 EP disclosed
CN-116457468-A Production of high-yielding recombinant chinese hamster ovary cell lines for therapeutic protein production 赛诺菲 2023-07-18 CN disclosed
WO-2023069727-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS EDISON ONCOLOGY (US) 2023-04-27 WO disclosed
WO-2022058603-A1 GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION SANOFI (FR) 2022-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043878-A1 GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION DHODH, GLUL, GLS2 GRM8 1875/4885GRM6 1940/4885GRM7 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.